Global News

Eli Lilly, BioNTech form immune system research collaboration

Wednesday, May 13, 2015 11:56 AM

Eli Lilly and Biopharmaceutical New Technologies (BioNTech), a Germany-based immunotherapy company, have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients.

More... »

Quest Diagnostics

Perrigo acquires Patheon's Mexican operations for $34 million in cash

Wednesday, May 13, 2015 11:54 AM

Perrigo, a consumer goods and pharmaceutical company headquartered in Ireland, has acquired the Mexican operations of Durham, N.C.-based Patheon for $34 million in cash.  The acquisition is expected to be immediately accretive to calendar 2015 adjusted EPS after the exclusion of estimates for intangible amortization and transaction-related costs.

More... »

Baxter BioScience acquires Oncaspar portfolio for leukemia

Wednesday, May 13, 2015 11:51 AM

Baxter International has signed a definitive agreement to acquire the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria. Baxter gains the marketed biologic treatment Oncaspar, the investigational biologic calaspargase pegol and an established oncology infrastructure with clinical and sales resources.

More... »

The Michael J. Fox Foundation, Imago Pharmaceuticals partner

Monday, May 11, 2015 03:15 PM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has acquired a library of research tools around the parkin protein from Imago Pharmaceuticals. The Foundation believes these tools—cell lines, plasmids, compounds and more—will accelerate biological study and drug development against this promising disease-modification target.

More... »

ERT completes acquisition of PHT

Monday, May 11, 2015 03:14 PM

ERT, a global solutions provider for patient safety and efficacy endpoint data collection headquartered in Philadelphia, Pa., has completed the acquisition of Boston, Mass.-based PHT, an eClinical innovator focused on the adoption of patient-driven mobile apps for improved clinical research. Financial terms of the transaction have not been disclosed.

More... »

UNC-Chapel Hill, GSK partner for HIV cure, launch Qura Therapeutics

Monday, May 11, 2015 02:06 PM

The University of North Carolina at Chapel Hill, a global public research university with experience in HIV basic and clinical research, and GlaxoSmithKline have created the dedicated HIV Cure Center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. This unique public-private partnership will redefine the traditional way of conducting research and create a new model to seek the breakthroughs needed to tackle a global health issue.

More... »

FDA lifts clinical hold on NeuroDerm’s ND0612 for Parkinson's

Monday, May 11, 2015 10:30 AM

The FDA has lifted the clinical hold on U.S. clinical studies of ND0612H and ND0612L, primary product candidates based on proprietary, subcutaneously-delivered Levodopa/Carbidopa (LD/CD) liquid formulation for the treatment of Parkinson's disease, owned by NeuroDerm, a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases. The hold was lifted after the FDA reviewed additional information related to the product candidates' delivery devices. U.S. clinical development of these product candidates is therefore cleared to proceed in the second half of 2015.

More... »

Surface Oncology appoints Detlev Biniszkiewicz CEO

Monday, May 11, 2015 09:09 AM

Surface Oncology, a Cambridge, Mass.-based provider of next-generation cancer immunotherapies, has appointed Detlev Biniszkiewicz, Ph.D., president and CEO, effective immediately. Biniszkiewicz brings over 15 years of industry leadership and experience building a transformative pipeline of novel cancer therapies, most recently as the head of the oncology strategy at AstraZeneca.

More... »

Assessing past performances

Monday, May 11, 2015 08:00 AM

The adage “Keep the past in the past” does not apply to clinical research best practices.

More... »

Plasmatech Biopharmaceuticals to acquire Abeona Therapeutics

Friday, May 8, 2015 12:24 PM

PlasmaTech Biopharmaceuticals, a Texas-based biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, has entered into a definitive agreement to acquire Abeona Therapeutics, a company engaged in the development and commercialization of therapies for patients with lysosomal storage diseases. The company will issue to Abeona Therapeutic members a total of 3,979,761 common shares upon closing of the transaction, and up to an additional $9 million in performance milestones, in common stock or cash, at the company’s option.

More... »



May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs